/Charles%20River%20Laboratories%20International%20Inc_%20chart%20and%20logo-by%20IgorGolovniov%20via%20Shutterstock.jpg)
Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) provides drug discovery, non-clinical development, and safety testing services. It is valued at a market cap of $7.6 billion.
Companies worth $2 billion or more are typically classified as “mid-cap stocks,” and CRL fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the diagnostics & research industry. By partnering with global research institutions and commercial disruptors, the company aims to accelerate the timeline from basic research to regulatory approval while maintaining a disciplined approach to capital allocation and operational efficiency.
